This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Events & Webinars

ASCO-GU 2023: The DEAR study

Darolutamide, Enzalutamide and Apalutamide in the Real-world for Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

NUBEQA® (darolutamide)

Description

In this on-demand video,

Professor Robert Jones
gives an update on a congress highlight presented at the 2023 American Society of Clinical Oncology Genitourinary (ASCO-GU) Symposium. Professor Jones discusses the results of the DEAR study on the real-world utilisation and outcomes of darolutamide, enzalutamide, and apalutamide in patients with nmCRPC, including discontinuation data and data on progression to metastatic castration-resistant prostate cancer (mCRPC).

NUBEQA Prescribing Information

Speakers

PP-NUB-GB-2022 | January 2025